Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Issued a Decision on the Regulation of Surgical Operations in Specialized Hospitals and Reminded Beauty Centers of the Legal Deadline Given until August to Settle their Situation

 
Deputy Prime Minister Health Minister Ghassan Hasbani held a press conference in his office at the Ministry of Public Health, Bir Hassan during which he tackled the organizational frames of beauty Centers and specialized hospitals.
He started by saying: “After the repetitive complaints received by the Ministry of Public Health on accidents and infringements occurring in the sector of Aesthetic Medicine, and as a result of what happened yesterday after the liposuction operation in a specialized hospital, we realized that it is our duty to inform you about the approach of the Ministry to the regulation of aesthetic sector and the actions taken and that being completed through regulatory actions."
 
Beauty Centers

He added: "The Ministry of Public Health followed up the work of the Parliamentary Health Commission for the regulation of Medical Beauty Centers licenses that resulted in the issuance of decision No. 30 of 10 February 2017, which was published in The Official gazette on February 16, 2017.  The Definition of Aesthetic Medicine, its centers and the medical work they are authorized to carry out are regulated by Law which has determined the medical specializations that have the right to hold a permission to practice the profession of Aesthetic medicine. According to the law, the existing Beauty Centers are given a 6 month period to regularize their legal situation as of the date of the publication of this law, i.e. 16 August 2017, under penalty of closing these centers by a decision of Health Minister.

Specialized Hospitals

Health Minister added that he has issued a regulatory decision for specialized hospitals related to the regulation of surgeries which stipulates the following:
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not be carried out in places other than specialized hospitals which include an intensive care division which holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent. 
Hasbani stressed that this decision will be immediately communicated to all concerned parties.

Death Case

Hasbani talked also about the recent tragic death of the woman who underwent a liposuction opertaion in a specialized hospital and said: “the Public Prosecution and the Syndicate of Physicians have launched investigations and the Ministry of Public Health has started to investigate and complete the files. The Committee of investigations will meet in the Ministry in order to consider the details of this case and provide consultancies to the Syndicate and Justice where needed.
    1
ATC Name B/G Ingredients Dosage Form Price
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution L.L
J05AR10 KALUVIA G Lopinavir - 200mg, Ritonavir - 50mg Tablet, film coated 7,632,790 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 2,080,268 L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 250mg/5ml 250mg/5ml Granules for suspension 477,384 L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 500mg 500mg Capsule 659,123 L.L
N03AX14 KEPAM MS G Levetiracetam - 500mg/5ml 500mg/5ml Injectable solution 9,170,015 L.L
N03AX14 KEPCITAM G Levetiracetam - 500mg 500mg Tablet, film coated 2,933,608 L.L
N03AX14 KEPCITAM G Levetiracetam - 1000mg 1000mg Tablet, film coated 3,119,058 L.L
N03AX14 KEPPRA B Levetiracetam - 250mg 250mg Tablet, film coated 3,240,855 L.L
N03AX14 KEPPRA B Levetiracetam - 500mg 500mg Tablet, film coated 6,245,576 L.L
N03AX14 KEPPRA B Levetiracetam - 1000mg 1,000mg Tablet, film coated 11,749,079 L.L
C03DA05 KERENDIA G Finerenone - 10mg 10mg Tablet, film coated 6,353,687 L.L
C03DA05 KERENDIA G Finerenone - 20mg 20mg Tablet, film coated 6,353,687 L.L
C07AB05 KERLONE B Betaxolol HCl - 20mg 20mg Tablet, film coated, scored 575,165 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 94,290,414 L.L
N01AX03 KETAMINE PANPHARMA G Ketamine HCl - 250mg/5ml 250mg/5ml Injectable solution 1,534,668 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 25mg 25mg Tablet, film coated 399,121 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable concentrated solution 435,405 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable solution 435,405 L.L
M01AB15 KETO-AVI G Ketorolac tromethamine - 30mg/ml 30mg/ml Injectable solution 106,164 L.L
D01AC08 KETOCONAZOLE KORHISPANA G Ketoconazole - 2% 2% Gel 599,354 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 10mg 10mg Tablet 268,769 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 30mg/2ml 30mg/2ml Injectable solution 268,769 L.L
M01AE03 KETOPROFENE MACOPHARMA G Ketoprofen - 100mg/100ml 100mg/100ml Injectable solution 329,241 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026